Kaposi sarcoma-associated herpesvirus infects monotypic (IgM lambda) but polyclonal naive B cells in Castleman disease and associated lymphoproliferative disorders.
about
An unusual presentation of Castleman's disease:a case reportKSHV: pathways to tumorigenesis and persistent infectionKaposi's Sarcoma–Associated Herpesvirus Immunoevasion and Tumorigenesis: Two Sides of the Same Coin?KSHV infects a subset of human tonsillar B cells, driving proliferation and plasmablast differentiation.Kaposi's sarcoma-associated herpesvirus-encoded LANA can interact with the nuclear mitotic apparatus protein to regulate genome maintenance and segregation.Establishment and maintenance of long-term murine gammaherpesvirus 68 latency in B cells in the absence of CD40.Spectrum of Kaposi's sarcoma-associated herpesvirus, or human herpesvirus 8, diseasesHow do viruses trick B cells into becoming lymphomas?Immunoglobulin light chain immunohistochemistry revisited, with emphasis on reactive follicular hyperplasia versus follicular lymphoma.Unique expression pattern of viral proteins in human herpesvirus 8-positive plasmablastic lymphoma: a case report.The latency-associated nuclear antigen of Kaposi sarcoma-associated herpesvirus induces B cell hyperplasia and lymphoma.CD20-negative diffuse large B-cell lymphomas: biology and emerging therapeutic options.Immunohistochemical detection of human herpes virus-8 latent nuclear antigen-1 is useful in the diagnosis of Kaposi sarcoma.Unraveling virus-induced lymphomagenesisKaposi sarcoma herpesvirus (KSHV) vFLIP oncoprotein induces B cell transdifferentiation and tumorigenesis in miceRituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman diseaseSubversion of B lymphocyte signaling by infectious agents.High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy.HIV-associated multicentric Castleman diseaseViral interleukin-6: role in Kaposi's sarcoma-associated herpesvirus: associated malignancies.β-HHVs and HHV-8 in Lymphoproliferative Disorders.BH3 Profiling Reveals Selectivity by Herpesviruses for Specific Bcl-2 Proteins To Mediate Survival of Latently Infected Cells.Clinical Manifestations of Kaposi Sarcoma Herpesvirus Lytic Activation: Multicentric Castleman Disease (KSHV-MCD) and the KSHV Inflammatory Cytokine Syndrome.Treatment of Kaposi sarcoma-associated herpesvirus-associated cancers.Episodic fevers and vasodilatory shock mimicking urosepsis in a patient with HIV-associated multicentric Castleman's Disease: a case report.Kaposi's sarcoma-associated herpesvirus-infected primary effusion lymphoma has a plasma cell gene expression profile.Kaposi's sarcoma-associated herpesvirus: clinical, diagnostic, and epidemiological aspects.Castleman disease.Kaposi's Sarcoma-Associated Herpesvirus Interleukin-6 Modulates Endothelial Cell Movement by Upregulating Cellular Genes Involved in Migration.Kaposi's sarcoma-associated herpesviral IL-6 and human IL-6 open reading frames contain miRNA binding sites and are subject to cellular miRNA regulation.Professional antigen presenting cells in human herpesvirus 8 infection.Kaposi's sarcoma-associated herpesvirus oncoprotein K13 protects against B cell receptor-induced growth arrest and apoptosis through NF-κB activation.Risk of malignant lymphoma associated with human herpesvirus-8: a case-control study in Spain.Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 and lymphoproliferative disordersThe product of Kaposi's sarcoma-associated herpesvirus immediate early gene K4.2 regulates immunoglobulin secretion and calcium homeostasis by interacting with and inhibiting pERP1.Viral studies in burkitt lymphoma: association with Epstein-Barr virus but not HHV-8.The malignant potential of HIV-associated Kaposi sarcoma.NF-κB as a target for oncogenic viruses.Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease.Efficient infection of a human B cell line with cell-free Kaposi's sarcoma-associated herpesvirus.
P2860
Q24803650-53AC60F4-16E3-47A9-980C-12513E1270C3Q27026000-82844338-072A-4958-986E-8B92B482FA91Q29394711-57471014-ADE9-4CFB-B429-2A18CC9D844EQ30433391-00CEA184-DC89-4136-AE42-E417CB8DBCEBQ30482603-2325F43D-A90C-4410-BD5F-AE249C752F4AQ33834753-2BA85B6D-9B21-40DE-8941-7C56DF6688B0Q33906970-98AFF2D2-3E49-4E58-A5D7-40F9EEE98EACQ34020096-9A9E3FFD-2AED-4AD6-BBB6-36C6506E6B02Q34070697-36912B14-CE90-4ED1-ACF1-1BBBD2D4CAB2Q34371885-154CB3BC-69BB-4CB2-AED7-C1B94B08200CQ34391203-D155D442-890E-4315-B798-FABD8B10F2BBQ34460823-ACA1C12B-2CCC-4E60-A5BB-534E71976FE5Q34545955-DD5F67CA-99A3-4ED9-A1AB-9A956B0230CAQ34614553-385A6669-54D7-45A9-A24E-B97ECA18B105Q34627126-79A7DDE8-E5B2-4498-B3C1-106945C05C4BQ34636851-4B805245-7286-47AD-A6D9-9BE0C7E94167Q35078625-6F8CC607-E545-4682-9637-B7FBA06C9CFAQ35127955-87D10A41-70C1-4DE0-A5F3-77E06C763952Q35226470-BA17D15E-3F63-4550-8B60-20F78D206227Q35550033-4A5EF5C5-3D20-4613-8B38-E7D898B0ACDFQ35560251-620B5C66-19C0-4E79-B359-063A25F7C7C0Q35641404-11AB15A4-1B56-4CFF-88D4-2BA8A2FB215FQ35795414-FEDA0DAE-26C7-4D8A-9D22-B5B9A2044516Q35895560-FBF5910B-F63F-4E72-86BD-EF880723C785Q35910542-29CE3C26-5047-487C-A159-B15BF651EF4CQ35918316-3110D143-64C1-427C-B896-0CEA488F6F6EQ36154559-8C99747B-6C66-4316-84A1-742780B26B50Q36297647-BD79B8D2-7537-4E95-852A-80ECD2FB8D82Q36364597-F9100254-26E2-45B9-A85B-DD0BD26912A9Q36483206-957175BF-08FF-4F6E-BBCA-7722E6A27B77Q36546999-06D05AAA-F5D3-4DE8-84B0-90C67940B9D0Q36607305-ACE236D9-5213-4C52-B216-4DCFCF894398Q36694262-A5622012-6B41-4205-AA7D-161A273B6511Q37016504-85B1C693-FCF5-4A15-9312-6B93F58100D9Q37254263-8CD64B54-456A-4BCC-886D-0EEDADE6DCEDQ37283699-83CC3CAE-A9CD-4370-8847-1C15CD317D07Q37314351-13884EA1-5797-4143-8532-03F52A0092FEQ37374081-CBB7A841-DFB6-4E96-9833-C77C8CCB9DF1Q37405468-6E81E5B3-D505-4A58-A1E5-E014CA08F12FQ37547223-9EBAD76D-AA9D-438F-B85D-17293EEF2427
P2860
Kaposi sarcoma-associated herpesvirus infects monotypic (IgM lambda) but polyclonal naive B cells in Castleman disease and associated lymphoproliferative disorders.
description
2001 nî lūn-bûn
@nan
2001 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Kaposi sarcoma-associated herp ...... lymphoproliferative disorders.
@ast
Kaposi sarcoma-associated herp ...... lymphoproliferative disorders.
@en
type
label
Kaposi sarcoma-associated herp ...... lymphoproliferative disorders.
@ast
Kaposi sarcoma-associated herp ...... lymphoproliferative disorders.
@en
prefLabel
Kaposi sarcoma-associated herp ...... lymphoproliferative disorders.
@ast
Kaposi sarcoma-associated herp ...... lymphoproliferative disorders.
@en
P2093
P356
P1433
P1476
Kaposi sarcoma-associated herp ...... lymphoproliferative disorders
@en
P2093
E Oksenhendler
P G Isaacson
R A Hamoudi
P304
P356
10.1182/BLOOD.V97.7.2130
P407
P577
2001-04-01T00:00:00Z